probenecid has been researched along with Neuroblastoma in 2 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Neuroblastoma: A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We used both in vitro cultures of neuroblastoma cell lines and nude-mice xenotransplants to explore the effects of co-administration of cisplatin and probenecid." | 7.83 | Probenecid Sensitizes Neuroblastoma Cancer Stem Cells to Cisplatin. ( Bahena, I; Campos-Arroyo, D; Carlos Martinez-Lazcano, J; Maldonado, V; Melendez-Zajgla, J; Patiño, N; Quintanar, V, 2016) |
| " One key challenge of DFMO is its rapid renal clearance and the need for high and frequent drug dosing during treatment." | 5.62 | Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma. ( Bachmann, AS; Dowling, TC; Schultz, CR; Swanson, MA, 2021) |
| " One key challenge of DFMO is its rapid renal clearance and the need for high and frequent drug dosing during treatment." | 1.62 | Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma. ( Bachmann, AS; Dowling, TC; Schultz, CR; Swanson, MA, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schultz, CR | 1 |
| Swanson, MA | 1 |
| Dowling, TC | 1 |
| Bachmann, AS | 1 |
| Campos-Arroyo, D | 1 |
| Maldonado, V | 1 |
| Bahena, I | 1 |
| Quintanar, V | 1 |
| Patiño, N | 1 |
| Carlos Martinez-Lazcano, J | 1 |
| Melendez-Zajgla, J | 1 |
2 other studies available for probenecid and Neuroblastoma
| Article | Year |
|---|---|
Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Chromatography, Liquid; Ef | 2021 |
Probenecid Sensitizes Neuroblastoma Cancer Stem Cells to Cisplatin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter | 2016 |